Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2Completed 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Polycystic Ovary Syndrome 2Metabolic Syndrome 2Carcinoma, Non-Small-Cell Lung 2Sleep Apnea, Obstructive 1Pancreatic Neoplasms 1Leukoplakia, Oral 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Insulin Resistance 1Inflammation 1Hypogonadism 1Glucose Intolerance 1Diabetes Mellitus 1

Interventions

Imatinib Mesylate 23Cyclophosphamide 18fludarabine 17fludarabine phosphate 13Busulfan 12Whole-Body Irradiation 11nilotinib 10Dasatinib 9thymoglobulin 8ponatinib 8Mycophenolic Acid 8Cytarabine 7Antilymphocyte Serum 7peginterferon alfa-2b 6Tacrolimus 6Cyclosporine 6Clofarabine 6Thiotepa 5Stem Cell Transplantation 4Sirolimus 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Melphalan 4Alemtuzumab 4sargramostim 3Interferon-alpha 3Homoharringtonine 3Cord Blood Stem Cell Transplantation 3Bortezomib 3zileuton 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Pioglitazone × Clear all
NCT02730195 2019-01-09

Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia

Emory University

Phase 2 Terminated
9 enrolled 8 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡